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Abstract
Background: In sub-Saharan Africa, where infectious diseases and nutritional deficiencies are common, severe
anaemia is a common cause of paediatric hospital admission, yet the evidence to support current treatment
recommendations is limited. To avert overuse of blood products, the World Health Organisation advocates a
conservative transfusion policy and recommends iron, folate and anti-helminthics at discharge. Outcomes are
unsatisfactory with high rates of in-hospital mortality (9–10 %), 6-month mortality and relapse (6 %). A definitive trial to
establish best transfusion and treatment strategies to prevent both early and delayed mortality and relapse is warranted.
Methods/Design: TRACT is a multicentre randomised controlled trial of 3954 children aged 2 months to 12
years admitted to hospital with severe anaemia (haemoglobin < 6 g/dl). Children will be enrolled over 2 years
in 4 centres in Uganda and Malawi and followed for 6 months. The trial will simultaneously evaluate (in a factorial trial
with a 3 x 2 x 2 design) 3 ways to reduce short-term and longer-term mortality and morbidity following admission to
hospital with severe anaemia in African children.
The trial will compare: (i) R1: liberal transfusion (30 ml/kg whole blood) versus conservative transfusion (20 ml/kg)
versus no transfusion (control). The control is only for children with uncomplicated severe anaemia (haemoglobin
4–6 g/dl); (ii) R2: post-discharge multi-vitamin multi-mineral supplementation (including folate and iron) versus
routine care (folate and iron) for 3 months; (iii) R3: post-discharge cotrimoxazole prophylaxis for 3 months versus
no prophylaxis. All randomisations are open. Enrolment to the trial started September 2014 and is currently ongoing.
Primary outcome is cumulative mortality to 4 weeks for the transfusion strategy comparisons, and to 6 months for the
nutritional support/antibiotic prophylaxis comparisons. Secondary outcomes include mortality, morbidity
(haematological correction, nutritional and infectious), safety and cost-effectiveness.
Discussion: If confirmed by the trial, a cheap and widely available ‘bundle’ of effective interventions, directed
at immediate and downstream consequences of severe anaemia, could lead to substantial reductions in mortality in a
substantial number of African children hospitalised with severe anaemia every year, if widely implemented.
Trial registration: Current Controlled Trials ISRCTN84086586, Approved 11 February 2013
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Background
In sub-Saharan Africa severe anaemia (SA) in children is
a leading cause of hospital admission, a major cause of
direct mortality [1] and a key factor in the approximately
600,000 malaria deaths/year [2]. Guidelines developed by
the World Health Organisation (WHO) encourage the
rational use of blood transfusion to preserve this scarce
resource and to reduce the risk of transfusion-transmitted
infections [3]. However, the evidence base supporting
these guidelines is weak, adherence is poor and national
transfusion recommendations vary between sub-Saharan
Africa countries [4]. Outcomes following SA are unsatis-
factory with high rates of in-hospital (9–10 %) [5]
and 6-month (12 %) mortality, and relapse or re-
hospitalisation (6 %) [6], indicating that the current
recommendations and their implementation are not
working in practice. Further, the aetiology of SA is
frequently multi-factorial, including potentially treat-
able co-morbidities such as bacteraemia and multiple
vitamin deficiencies – key determinants of outcome
[7] that are not addressed in current treatment guide-
lines. Although the 2 most recent systematic reviews
(both published in 2000) indicated the need for for-
mal evaluation of the restrictive transfusion policy
supported by the World Health Organisation (WHO)
in a controlled trial [5, 8], little progress has been
made in the intervening decade. The poor outcomes
and recurrent morbidity of children with SA warrant
a definitive trial to establish best transfusion and
treatment strategies to prevent both early and delayed
mortality and relapse.
Current WHO recommendations
Transfusion
To avert overuse of blood products the WHO advocates
a conservative transfusion policy, reserving blood for
children with a haemoglobin (Hb) < 4 g/dl (or < 6 g/dl if
accompanied by complications). Although not systemat-
ically evaluated, this conservative transfusion policy has
been incorporated in WHO paediatric hospital practice
guidelines. However, the specific recommendations in
these guidelines contain inconsistencies and ambiguities
[9] resulting in variation in practice across African coun-
tries, most particularly in the subgroup with ‘uncom-
plicated’ SA (Hb 4–6 g/dl without severe symptoms)
where transfusion avoidance is recommended [4, 8].
A Cochrane review including the only 2 African rando-
mised controlled trials (RCTs) [10, 11] conducted to date
(involving 114 and 116 children randomised to blood
transfusion or oral haematinics) concluded that there was
insufficient information on whether routinely giving blood
to clinically stable children with SA either reduces death
or results in a higher haematocrit measured at 1 month,
and indicated the need for a definitive trial [8].
Overall mortality in children with Hb < 4 g/dl or SA
with life-threatening complications is 15 % [5]. Clinical
studies in Kenya [12, 13] have shown that profound an-
aemia (Hb < 4 g/dl) is independently associated with
death (odds ratio; OR = 2 · 5), as is SA (defined in this
study as a Hb < 5 g/dl) complicated by reduced con-
sciousness (OR = 7 · 4) or respiratory distress (OR = 4 · 1).
Many deaths occur within 48 hours of admission, with
25–50 % [14, 15] occurring within 6 hours. In the FEAST
trial, which enrolled children with shock, a higher case fa-
tality was found in those with anaemia compared to those
without anaemia, irrespective of intervention group [16].
In children with uncomplicated SA – Hb 4–6 g/dl without
prostration or respiratory distress – overall case fatality is
4–6 %, being lower in parasitaemic children (2–3 %) [17]
than in those with negative malarial slides (8–10 %) [12].
The ratio of complicated to uncomplicated SA is com-
monly 1:1 [18].
Current transfusion guidelines are conservative not
only in terms of criteria applied for administering a
transfusion at all, but also in terms of the volume of
blood transfused. Currently, 20 ml/kg of whole blood
(or 10 ml/kg packed cells) are recommended for all
levels of anaemia below Hb < 6 g/dl [19]. Using stand-
ard formulae to calculate volume required [20] this
under-treats children with profound anaemia by ap-
proximately 30 % and this volume may not, therefore,
be sufficient to correct anaemia [4].
Other treatment recommendations for severe anaemia
WHO treatment guidelines deal specifically with acute
treatment of malaria and with folate and iron deficiency,
together widely held as the most important causes of
anaemia. There are no specific recommendations for
subsequent infection prophylaxis (including against
malaria) [3]. In the only comprehensive case-control
study (SeVana) of children hospitalised with SA in Africa
[7], key aetiological factors for SA were bacteraemia
(OR = 5.3; 95 % confidence interval; CI 2.6–10.9),
malaria (2.3; 1.6–3.3), hookworm (4.8; 2.0–11.8), HIV
infection (2.0; 1.0–3.8), vitamin A deficiency (2.8; 1.3–5.8)
and vitamin B12 deficiency (2.2; 1.4–3.6). A subsequent
publication, reporting the long-term outcome of children
in this study, HIV infection was found to be the major risk
factor both for 18-month post-discharge mortality (hazard
ratio (HR) 10.5, 95 % CI 4.0–27.2) and for recurrence of
SA (HR 5.6, 95 % CI 1.6–20.1). Children admitted with
bacteraemia were also at an increased risk of post-
discharge all cause mortality (HR 2.2, 95 % CI 0.8–5.6).
With respect to current treatment recommendations nei-
ther iron nor folate deficiencies were factors for SA being
less prevalent among cases than controls (without SA) in
the SeVana study. Thus, although folate supplementation is
recommended, folate deficiency was not found in the
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Malawian SeVana study [6], in agreement with previous re-
ports [21] and observations that folate supplementation in
anaemic children with malaria failed to raise Hb concen-
trations [22]. Moreover, vitamin B12 and vitamin A supple-
mentation are not recommended in guidelines for the
management of SA. Iron supplementation is effective for
reduction of iron deficiency and anaemia in iron-deficient
children. However, a community-based randomised con-
trolled trial in Zanzibar designed to evaluate the impact of
zinc and iron plus folic acid supplementation on morbidity
and mortality in young children showed that supplementa-
tion may also be associated with adverse effects, specifically
increased risk of hospitalisation (primarily due to malaria
and infectious disease), and mortality in malaria-endemic
areas [23]. The WHO has revised its recommendations to
advise that iron and folic acid should only be targeted to-
wards those who are anaemic and at risk of iron deficiency.
Establishing iron status in children hospitalised with SA,
and more generally in paediatric populations living in mal-
arial areas, is technically challenging [24, 25] and is rarely
available in resource-limited hospitals, making the imple-
mentation of WHO guidelines challenging in the very
areas that are most affected. The development of
micronutrient powders (eg Nutromix™ or Sprinkles™;
Hexagon Nutrition Pvt Ltd, Nashik, Maharastra, India),
as a novel approach for delivering iron and other
micronutrients, offers a chance to correct relevant nu-
trient deficiencies [26] and provide iron in lower doses;
with good adherence in population-based studies [27].
With regard to infection prophylaxis the substantial
mortality benefits (allied with extremely low rates of tox-
icity) associated with cotrimoxazole prophylaxis in HIV-
infected children [28] have generally been attributed to
reductions in bacterial infections [29, 30]. Of note, these
benefits have been observed even in areas of high back-
ground resistance [31]. The fact that mortality bene-
fits cannot be attributed solely to pneumonia [29, 30]
raises the intriguing possibility that cotrimoxazole
may act on a number of different pathways – the
most important with regards to SA relapse being en-
teropathy and intestinal permeability, although any
benefits of cotrimoxazole on microbial translocation
and/or systemic immune activation, or on reducing
recurrent infections during recovery from SA, could
also impact longer-term morbidity. Cotrimoxazole has
been shown to be effective in preventing malaria in
HIV-uninfected children aged > 5 years [32], and in
HIV-exposed uninfected (HIV-uninfected children
born to HIV-infected mothers) and HIV-infected chil-
dren [33], despite high levels of background parasite
resistance to sulphamethoxazole.
In summary, the best available evidence suggests that
key factors for poor long-term outcome following SA hos-
pitalisation are nutritional factors and recurrent bacterial
infection, the strongest potentially modifiable underlying
causes of morbidity and mortality which we propose to
address in this trial.
Methods/Design
Study objectives
The primary objective of the trial is to identify effective,
safe and acceptable interventions to reduce short-term
and longer-term mortality and morbidity following ad-
mission to hospital with SA in sub-Saharan Africa. There
are 2 hypotheses being tested:
1) A liberal rather than a conservative blood
transfusion policy will decrease mortality
(cumulative to 4 weeks) in children admitted to
hospital with SA (Hb < 6 g/dl).
2) Supplementary multi-vitamin multi-mineral
(MVMM) treatments or additional cotrimoxazole
prophylaxis or both for 3 months post discharge
will reduce rates of readmission, SA relapse,
re-transfusion or death (cumulative to 6 months)
compared to current recommendations (iron and
folate) and anti-helminthics in all (anti-helminthics if
aged > 1 year).
Secondary objectives
i. To identify the most cost-effective interventions to
reduce early mortality, and assess their budget impact
ii. To determine efficacy of long-term support strategies
(MVMM and cotrimoxazole prophylaxis) on other
markers of nutritional status and causes of death
iii. To determine the effect of transfusion strategies
and long-term support strategies on markers of
inflammation and immunological activation and
function
iv. To identify the mechanism of action of the most
effective interventions through focussed investigations
of human genetic polymorphisms, molecular
diagnostics, immunological activation, markers of gut
barrier dysfunction, and haematological and
nutritional response
Study design and population
TRACT is a multicentre randomised controlled trial of
3954 children aged 2 months to 12 years admitted to
hospital with a Hb < 6 g/dl. Children will be enrolled
over 2 years from 2 countries and followed for 6 months.
The trial will simultaneously evaluate 3 ways to reduce
short-term and longer-term mortality (primary end-
point) and morbidity following admission to hospital
with SA in sub-Saharan Africa using a 3 x 2 x 2 factorial
design. All randomisations will be open. Inclusion/exclu-
sion criteria are detailed in Table 1.
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Trial interventions
Each intervention addresses one of the potential ap-
proaches to reducing mortality and morbidity in children
with SA (Fig. 1: Trial flow schema)
R1: Immediate liberal transfusion (30 ml/kg) versus
immediate conservative transfusion (20 ml/kg) versus
no transfusion (the last strategy only for children with
uncomplicated SA with Hb 4–6 g/dl).
R2: Post-discharge MVMM supplementation for 3
months (which includes folate and iron) and anti-
helminthics if aged > 1 years versus routine care (folate
and iron at standard treatment doses (varies with age)
for 3 months) and anti-helminthics if aged > 1 year.
R3: Post-discharge cotrimoxazole prophylaxis for 3
months versus no prophylaxis.
R1 addresses both conservative aspects of current
guidelines: ‘whether to give blood’ in uncomplicated SA
(4-6 g/dl without complications), and ‘how much blood
to give’ in all children with SA. The transfusion and
post-discharge interventions will be open-label for rea-
sons of practicality and compliance.
Potential for interactions between the trial interventions
Because the transfusion, nutritional and antibiotic
prophylaxis interventions approach different mecha-
nisms for reducing short-term and long-term mortality/
morbidity following SA, we consider that important inter-
actions between randomised groups are unlikely. Further,
any interactions that do exist are likely to be quantitative
(slightly smaller/larger effects) rather than qualitative
(effect on one background, no effect on another).
Ethics approvals
The trial protocol was reviewed and obtained approval
from the Imperial College Research Ethics Committee
(ICREC_13_1_11). In Uganda the trial was approved by
the Research Ethics Committee in Uganda, Makerere
University School of Medicine Research and Ethics
Committee, Kampala (#REC ref 2013–050) and in Malawi
by the College of Medicine Research and Ethics Commit-
tee, (P.03/13/1365). In both countries regulatory author-
ities’ approval was also received.
Consent
Prospective written, informed consent will be obtained
from parents or guardians of children who are considered
to be sufficiently stable. Parents or guardians will be given
an information sheet in their usual language containing
details of the TRACT trial. The sheet will be read aloud to
those who are unable to read. Parents and guardians will
be encouraged to ask questions about the trial prior to
signing the consent form. The right of the participant to
refuse to participate without giving reasons must be
respected. However, we anticipate a number of children
presenting as emergencies where delay in study enrolment,
and thus treatment, through a consent procedure would
be unacceptable. A two-stage consent process in this cir-
cumstance and the details are covered under section
‘Consent process for severe life-threatening anaemia’ below.
Treatments given in the trial
Standard management
All trial patients will receive standard of care (SOC) in-
cluding antibiotics (given intravenously or orally) and/or
anti-malarial drugs following national guidelines, based
on WHO syndromic patient management [3]. We will
collect data on all administered drugs. Antipyretics, anti-
convulsants and treatment for hypoglycaemia will be ad-
ministered according to nationally agreed protocols. If
required, maintenance fluids will be run at 3–4 ml/kg/
hour irrespective of age until the child can drink and re-
tain oral fluids. At discharge from hospital all aged chil-
dren > 1 year will be receive empiric treatment for
helminths (500 mg mebendazole or 400 mg albendazole
in Malawi) in accordance to current recommendations
(SOC) regardless of randomised allocation.
Trial treatments
Randomisation procedures
Randomisation in each part of the factorial will be strati-
fied by centre and the other randomisations in the fac-
torial. Randomisation lists, using variable block sizes,
will be generated and kept at the Medical Research
Council Clinical Trials Unit (MRC CTU), London. The
randomisation envelopes and clinical packs will be pre-
pared before the trial, with 1 set for complicated SA
(R1a) and 1 for uncomplicated SA (R1b). Eligible children
will be screened and recruited at the time of hospital ad-
mission. At enrolment sealed consecutively numbered
opaque envelopes (opened in strict numeric order) will as-
sign a TRACT trial number and indicate a clinical pack
number. The clinical pack will be within the first 10 packs
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Aged 2 months to 12 years Malignancy or other terminal illness
Severe anaemia (Hb < 6 g/dl) on
the day of admission to hospital
Acute trauma or burns as main reason
for admission
Care-giver willing/able to
provide consent
Surgery as main reason for admission
Chronic renal or liver failure
Signs of bi-ventricular heart failure
Known congenital or valvular heart
disease (non-surgically corrected)
Children who are exclusively breast fed
(thus unable to take nutritional support)
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Fig. 1 Trial scheme for the Transfusion and Treatment of severe anaemia in African children trial (TRACT)
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in the study filing cabinet but will not necessarily be the
first remaining clinical pack number (an additional level
of allocation concealment). Once opened, the clinical pack
contains case report forms (CRFs) and a card which con-
firms the TRACT trial number, and simultaneously as-
signs transfusion interventions R1a/b (according to SA
strata), micronutrient support (R2) and antimicrobial
prophylaxis (R3) randomly. A similar system has worked
well in the emergency care trial, FEAST [16].
The randomisation procedures and adherence to allo-
cated treatments are reviewed at each independent moni-
toring visit. The process for this is detailed within the
monitoring Standard Operating Procedure (SOP). The
monitors are requested to check at each participating site
whether: a) the randomisation envelopes are being cor-
rectly stored and used; b) whether enrolled children are al-
located to the correct arm and c) that the allocated trial
treatments (transfusion, MVMM/iron or folate and cotri-
moxazole) were received by the child. It is also monitored
electronically through central database monitoring, and
also that both the Data Monitoring Committee (DMC)
and the Trial Steering Committee (TSC) will monitor
overall adherence to each of the randomised allocations.
R1 transfusion strategies
At enrolment children will be assessed at admission and
will be divided into 2 groups for randomisation (R1a and
R1b: see Table 2) based on: i) haemoglobin level, and ii)
assessment of clinical severity children or complications
(reduced conscious level; respiratory distress, acute his-
tory of haemoglobinuria or an established diagnosis of
sickle cell disease).
R1a complicated severe anaemia
Children fulfilling these severity criteria will be randomly
allocated on a 1:1 basis to receive one of the following:
○ Whole blood transfusion 20 ml/kg, alternatively
10 ml/kg packed cells; or
○ Whole blood transfusion 30 ml/kg, alternatively
15 ml/kg packed cells
R1b uncomplicated severe anaemia
Children with an Hb 4–6 g/dl without any severity fea-
tures will be randomly allocated on a 1:1:2 basis to re-
ceive one of the following:
○ Whole blood transfusion 20 ml/kg alternatively
10 ml/kg packed cells, or
○ Whole blood transfusion 30 ml/kg alternatively
15 ml/kg packed cells, or
○ No transfusion (control, SOC)
Transfusion treatment schedule
A clinician or medical officer will prescribe the blood,
using a calculator, to determine the volume of whole
blood required (20 or 30 ml/kg). If only packed cells are
available then the clinician must re-calculate the equiva-
lent volumes of packed cells (10 or 15 ml/kg). Transfu-
sions will be administered in gauged blood burettes; an
initial aliquot (2 ml) will run into a sterile apex tube
using an aseptic technique (and ensuring that the tip of
the infusion set does not touch anything, to prevent con-
tamination) and 1 drop taken from this to record the Hb
and haematocrit of the donor blood. Whole blood will
be run over 3–4 hours and packed cells can be adminis-
tered over 2–3 hours.
For all children in the trial an additional, or initial (for
SOC control group in R1b only), transfusion(s) will be
permitted after 8 hours (at the point of the first reassess-
ment of Hb) for children who still have either: (i) pro-
found anaemia Hb < 4 g/dl, irrespective of other signs of
severity; (ii) SA 4–6 g/dl and one or both de novo signs
of severity (respiratory distress or impaired conscious-
ness); (iii) uncorrected SA 4–6 g/dl in children with an
acute history of haemoglobinuria or known sickle cell
disease. Early sampling of Hb (<8 hours from baseline),
and additional transfusion, will be permitted in children
randomised to any group in the R1b strata (uncompli-
cated SA) developing de novo signs of severity.
If a child randomised to no-transfusion control (R1b
only) meets the above criteria, they will receive 20 ml/kg
whole blood or 10 ml/kg packed cells, as recommended
by the WHO [3]. Children randomised to initially re-
ceive blood (R1a and R1b) who subsequently meet the
above criteria will follow their randomisation arm: that
is they will receive either an additional transfusion of 20
ml/kg or 30 ml/kg of whole blood (or 10 ml/kg or 15
ml/kg packed cells respectively). Any child who has
already received 2 transfusions and subsequently fulfils
the criteria above will receive a maximum of 20 ml/kg
(or 10 ml/kg packed cells) irrespective of randomisation.
Frusemide or other diuretics will be prescribed at the
discretion of the attending physician and not used rou-
tinely in the trial.
R2 micronutrient support
Simultaneously to R1 randomisations, all children entering
the trial will also be randomly allocated on a 1:1 basis to
receive either multi-vitamin multi-mineral mix (MVMM:
Nutromix™ which contains iron, folate and other MVMM)
or iron and folate alone (at WHO-recommended
doses) for 3 months post discharge. Nutromix™ has been
Table 2 Transfusion sub-groups
R1a Complicated severe anaemia: Hb < 4 g/dl or a Hb < 6 g/dl plus 1 or
more signs of severity or complications
R1b Uncomplicated severe anaemia: Hb≥ 4 and < 6 g/dl without any of
the severity features or complications
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specifically designed for children of 6–24 months of age
with SA [34–36]. The formulation, meets the recom-
mended nutrient intake (RNI), particularly for vulnerable
groups during emergencies [37]. RNI is defined as the
daily dietary intake of a nutrient sufficient to meet the nu-
trient requirements of nearly all apparently healthy indi-
viduals in a specific population group, usually by age and
sex. The dosage is 1 sachet to be taken daily by the child
[26] and will be prescribed at the time of discharge from
hospital (or 5 days from randomisation in those not dis-
charged by this timepoint). In those children receiving
iron (syrup or tablets) and folate tablets, for children aged
< 2 years the recommended dosages are 25 mg iron: 100–
400 μg folate; and for children > 2 years and < 12 years, 60
mg iron: 400 μg folate. Iron, folate and MVMM will all be
given for 3 months, according to WHO guidelines for the
management of SA.
The use of nutritional supplementation, including
MVMM randomisation, will be pragmatic in that all
children for whom these supplements should be re-
ceived, according to WHO or national guidelines (e.g.
those initially admitted with severe malnutrition), will
receive them. Children aged < 6 months who are not
weaned (fully breast-fed) will be excluded from the trial.
For children with severe malnutrition, iron-containing
supplements are not recommended during the first 7
days of acute rehabilitation (WHO guidelines) [3] but
can be used effectively after this. For children with se-
vere malnutrition discharged on ready-to-use thera-
peutic food (RUTF) which contains MVMM, children
will essentially ignore their allocated MVMM random-
isation, but will receive their standard post-discharge
supplementation within the RUTF which would be re-
corded on study CRFs. The number of children with se-
vere malnutrition as their admission diagnosis is expected
to be small (< 5 %).
R3 antimicrobial prophylaxis
Children will be randomly allocated on a 1:1 basis to re-
ceive either receive: (i) cotrimoxazole prophylaxis for 3
months post discharge or (ii) no antibiotic prophylaxis
post discharge (control, SOC). Cotrimoxazole dispersible
tablets (240 mg: trimethoprim 40 mg/sulphamethoxazole
200 mg) will be used and dosing will follow WHO rec-
ommendations for prophylaxis in HIV-infected children:
age 2 to 6 months: 120 mg; age 6 months to 5 years: 240
mg; children > 5 years: 480 mg [38]. The dispersible tab-
lets may be taken with water or mixed with feeds. Cotri-
moxazole will be prescribed from discharge (or 5 days
from randomisation in those not discharged by this
timepoint). The cotrimoxazole prophylaxis randomisa-
tion will be pragmatic in that all children for whom
cotrimoxazole prophylaxis should be prescribed accord-
ing to WHO or national guidelines (e.g. HIV-infected
children) will receive it regardless of randomisation, and
no child in whom it is contraindicated (e.g. known
GP6D deficiency according to local testing) will receive
it. Such children will essentially ignore their allocated
cotrimoxazole randomisation; any cotrimoxazole re-
ceived per guidelines would be recorded on study CRFs.
The number of children with these conditions is ex-
pected to be small (< 5 %). HIV-infected children will re-
ceive antiretrovirals and will continue in the trial with
HIV management and follow-up tailored in collabor-
ation with local HIV clinics.
Co-enrolment guidelines
Patients will not ordinarily be permitted to participate in
any other clinical intervention trial or research protocol
while on the TRACT trial. Participation in other studies
that do not involve an intervention may be acceptable,
following agreement from the TRACT trial management
group (TMG). The TRACT TMG will consider co-
enrolment of TRACT participants onto other trials where
the interventions do not conflict with the TRACT objec-
tives on a case-by-case basis.
Measurement of endpoints
Assessment during hospital
The clinicians will complete a detailed clinical review on
the CRF and perform a physical examination at enrol-
ment. A symptom checklist and targeted physical exam-
ination will be performed at each subsequent clinical
assessment. Children will be intensively monitored on
the day of admission by the clinical team, and during
any transfusion and then reviewed daily by the study
team until discharge, with Hb testing performed at least
8 hourly in the first 24 hours, and daily thereafter. At
each review conscious level, vital signs (heart rate, oxy-
gen saturation, respiratory rate, axillary temperature,
blood pressure) will be recorded, and examinations will
specifically review the child for solicited adverse events.
The doctor will be responsible for documenting and
reporting serious adverse events (SAEs). Admission and
final diagnoses will be recorded in the CRF.
Follow-up
A symptom checklist and targeted physical examination
will be performed at each clinic visit post discharge.
Medical history since last visit including hospital re-
admissions, transfusions, specific solicited adverse events,
and grade 3 or 4 adverse events related to nutritional and
antibiotic interventions will be documented by a doctor,
including severity and likely relationship of any adverse
events to trial interventions. At Day 28 adherence to and
acceptability of MVMM and/or cotrimoxazole will be
queried by carer self-report, and carers will be provided
with a supply of drugs sufficient to last for the next 2
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months (Day 90 since admission). Blood and other tests
and sample storage will require a maximum of 4 mls
heparinised blood (plasma) and 1 ml into ethylenedi-
aminetetraacetic acid (EDTA) (for pathogen diagnostics).
At Day 90, adherence/acceptability will again be recorded,
but no more supplements/antibiotics will be given. Any
participants requiring further care at their Day 180 visit
will transferred into the routine clinics at the centre where
the trial is being conducted. Locator maps and contact
numbers will be obtained to facilitate follow-up.
Withdrawing from the trial and protocol treatment
discontinuation
In consenting to the trial, parents or guardians and chil-
dren are consenting to trial treatment, data collection
and follow-up. If a patient chooses to discontinue any
part of their trial treatment, they should always be en-
couraged not leave the whole trial and to return for
follow-up, providing they are willing. After the partici-
pant has entered the trial the clinician remains free to
give alternative treatment to that specified in the proto-
col at any stage if he/she feels it is in the participant’s
best interest, but the reasons for doing so should be re-
corded. In these cases the participants remain within the
study for the purposes of follow-up and data analysis.
All carers and participants are free to withdraw at any
time from the protocol treatment without giving reasons
and without prejudicing further treatment. If they do
not wish to remain on trial follow-up, however, their de-
cision will be respected and the patient will be with-
drawn from the trial completely.
Withdrawal from the transfusion intervention or control
arms is unlikely, given that most transfusions are given
within the first 12 hours of admission. Severe allergic reac-
tion (toxicity) or Transfusion Related Acute Lung Injury
(TRALI) is included as a secondary endpoint and is rele-
vant only to children receiving transfusion. It will not be a
reason to withdraw the child from the trial, but further
transfusions should be withheld. The child should con-
tinue with their cotrimoxazole/MVMM allocation wher-
ever possible.
Outcomes
Primary outcome and secondary outcomes are detailed
in Table 3. The methods for assessing efficacy include:
Clinical events
Survival status will be recorded at discharge and each
subsequent visit (28 days, 90 days and 180 days follow-
ing admission). Any patient lost to follow-up before 6
months without withdrawing consent will be traced for
vital status. Other SAEs will be reported as and when
the doctor becomes aware of them. The details reported
will include bedside observations, laboratory data, and
additional clinical narrative. During the index admission,
any child fulfilling criteria for a new or additional trans-
fusion will be recorded. At all subsequent visits hospital
admissions and requirement for transfusion will be
solicited.
Haematological recovery
Haemoglobin will be recorded at 8-hour periods up to
24 hours, then daily until discharge, then at 28 days, 90
days and 180 days.
Safety and adverse event reporting
The symptom checklist used at each visit will explicitly
prompt for symptoms relating to possible drug toxicities.
Additional safety blood tests or investigations may be
performed to investigate symptoms or monitor emergent
laboratory test abnormalities as clinically indicated.
Serious, solicited and grade 3 or 4 adverse events will be
reported on the CRF. Adverse events (clinical and la-
boratory) will be graded according to toxicity/severity
grading.
Adherence
Adherence to nutritional and prophylaxis drugs will be
assessed in all participants at each visit by pill counts for
tablets, and nurse-administered questionnaire to the
Table 3 Outcome measures
Primary outcome
Cumulative mortality to 28 days for the transfusion strategy
comparison, and to 180 days for the nutritional support/antibiotic
prophylaxis comparison
Secondary outcomes
Mortality: at 48 hours, 28 days, 90 days and 180 days (cumulative)
where not the primary outcome
Morbidity: endpoints relating to the specific mechanisms of action of
each intervention:
re-admission to hospital
haematological:
proportion achieving correction of anaemia (defined by the WHO
as Hb > 9 g/dl) at 48 hours, 28 days, 90 days and 180 days
development of new profound anaemia (Hb < 4 g/dl) during acute
admission or development of severe anaemia (Hb < 6 g/dl) post
discharge
nutritional: changes in weight and mid-upper arm circumference
(MUAC) at 90 days and 180 days
anti-infection: changes in inflammatory markers (C-reactive protein
(CRP) , procalcitonin), incidence of bacterial infections and malaria
at 28 days, 90 days and 180 days
solicited adverse events: suspected transfusion reactions: febrile
reactions, TRALI (Transfusion Related Acute Lung Injury) (any grade);
grade 3–4 toxicity of cotrimoxazole, MVMM or standard iron/folate
serious adverse events
costs and cost-effectiveness
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child’s carer, and where appropriate to the child (at the
discretion of the nurse or doctor depending on age).
Health economics
The trial will measure healthcare-related costs in trial
participants, starting at randomisation and continuing
for the duration of follow-up. Information on hospitali-
sations (number, reason, and duration of stay) and other
healthcare resource utilisation (visits to healthcare cen-
tres, medications) will be collected by carer interview at
the 28-day, 90-day and 180-day visits. The economic
evaluation will be conducted from the health services
perspective. Unit costs will be attached to resource use,
using the best available estimates of long-run marginal
opportunity cost, to obtain a cost per patient over the
period of follow-up. Routinely available national unit
costs will be used where possible with local estimations
where necessary. There will also be a budget impact ana-
lyses of the consequences of adopting the interventions
on the health sector budgets, in each of the countries of
the trial.
Anti-infective
Changes in inflammatory markers (eg CRP) (all partici-
pants) will be measured retrospectively together with the
incidence of bacterial infections, acute febrile illness and
malaria at 28 days, 90 days and 180 days from carer
interview, blood cultures and non-culture-based molecu-
lar diagnostics on stored samples.
Methods of reducing bias
Protection against bias is principally provided by a com-
pletely objective primary endpoint (mortality). Any child
lost to follow-up before 6 months will be traced for vital
status. Cause of death (and other clinical secondary end-
points) will be adjudicated by an Endpoint Review Com-
mittee (ERC), blinded to randomised allocations. The
ERC will adjudicate on causes of death and whether fatal
and non-fatal SAEs were unlikely, possibly/probably or
uncertainly related to each of the randomised interven-
tions (transfusion volume, MVMM, cotrimoxazole), if
the child were to be receiving them (without knowledge
of actual randomisation), to protect from bias in this
open trial. The randomisations to transfusion strategies
and long-term support are open because of logistical
constraints – it is impossible to blind transfusion or nu-
tritional strategies since MVMM is in a sachet and iron
and folate are largely provided separately as a syrup and
crushable tablets or tablets alone. Whilst cotrimoxazole
prophylaxis could be blinded, the intention of this prag-
matic strategy trial is to also assess likely impacts of
non-compliance to taking cotrimoxazole on an antibiotic
prophylaxis strategy in SA.
Sample size calculation and statistical analysis
Sample size
The sample size calculation is based on the following
assumptions:
 80 % power, 2-sided alpha = 0.013 to allow for 4
comparisons (see below)
 SA cases are 50 % complicated (< 4 g/dl or 4–6 g/dl
with prostration/respiratory distress/known sickle
cell disease/haemoglobinuria) and 50 %
uncomplicated (4–6 g/dl without prostration,
respiratory distress, known sickle cell disease or
haemoglobinuria) [12] (and Dr. Olupot-Olupot
personal communication)
 Mortality (cumulative) at 48 hours and 4 weeks is 11
% and 16 % respectively in complicated SA, and 4 %
and 9 % in uncomplicated SA
 The cumulative rate of re-admission, SA relapse and
re-transfusion at 6 months is 12.5 % in both
complicated and uncomplicated SA (in addition to
mortality above)
 For the primary comparison of transfusion versus no
transfusion in uncomplicated SA at 4 weeks, the
minimum clinically relevant difference is a 50 %
relative reduction (R1b): for the other primary
comparison of transfusion volume (20 versus 30 ml/
kg) at 4 weeks (R1a and 1b), the minimum clinically
relevant difference is a 30 % relative reduction. The
minimum clinically relevant difference is larger for
the transfusion versus no transfusion question as
provision of safe blood at all will require greater
resources than provision of slightly larger versus
slightly smaller blood volumes. As the same relative
difference translates to a far larger absolute
difference at higher event rates, for the primary
comparison at 6 months (R2/3) the minimum
clinically relevant difference is a 5 % absolute
reduction (see below for control group event rates).
Then:
(R1b) comparison of transfusion versus no
transfusion (50 % reduction from 9 % control
mortality at 4 weeks) requires 1460 uncomplicated
SA cases (1:1 allocation to 30/20 ml/kg:no
transfusion, 730 in no transfusion group, 365
receiving 20 ml/kg and 365 receiving 30 ml/kg
transfusions)
(R1a and 1b) if the overall ratio of
uncomplicated:complicated SAs is 1:1 (ie 50 % of
each type), then within the subgroup randomised
1:1 to 30 versus 20 ml/kg, the ratio will be 1:2
because this comparison excludes the 50 % of
uncomplicated SA randomised to no transfusion.
Overall mortality at 4 weeks in this group will,
therefore, be 13.67 % (0.33 × 9 % + 0.67 × 16 %).
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The comparison of 30 versus 20 ml/kg (30 %
reduction, to 9.57 %) requires 2798 SAs, 1399 per
group (split 466 uncomplicated, 933 complicated)
Therefore, comparing required sample sizes for
R1a and R1b, to address both parts of the
transfusion question (R1) we need slightly more
uncomplicated SA children per group from (R1a
and 1b – n = 466) than (R1b – n = 365), and
therefore the total sample size is 3730 cases
(933 × 2 = 1866 complicated, 466 × 4 = 1864
uncomplicated)
(R2/3) the comparison of multi-vitamins versus
SOC (1:1) and cotrimoxazole prophylaxis versus
SOC (1:1) requires 3162 SA cases, assuming 50 %
are complicated and 50 % uncomplicated, to
detect a 5 % absolute reduction from average
control mortality of 25 % (0.5 × 21.5 % + 0.5 ×
28.5 % at 4 weeks).
Thus, a sample size of 3730 SA cases would allow the
multiple comparisons above to be made. Assuming a 6 %
loss to follow-up by 6 months increases this to 3954 SA
cases. As the effect sizes are reasonably large on the rela-
tive scale (> 30 % reduction), inflation factors which adjust
for the factorial design are close to 1. However, assump-
tions are more sensitive to the relative contribution of
uncomplicated:complicated SA. Capping the uncompli-
cated SA strata at 2000 cases (ie recruiting at least 1950
complicated SA) retains at least 80 % power to detect the
differences above independently of variations in the con-
tributing proportions of complicated SA.
Randomising uncomplicated SA (R1b) 1:1:2 between
30 ml/kg:20 ml/kg:no transfusion provides greater power
for the comparison of no transfusion (SOC) versus
transfusion in this group because the final randomisation
ratio for transfusion:no transfusion is 1:1. In contrast, a
1:1:1 randomisation in this strata would produce a 2:1
transfusion:no transfusion ratio which has lower power.
Statistical analysis
The analyses will be described in detail in a full Statistical
Analysis Plan. In brief, each intervention is hypothesised
to be superior to SOC and, therefore, the proposed ana-
lysis is intention-to-treat, including all randomised pa-
tients. The primary analysis will compare: a) transfusion
versus no transfusion (strata b only) and b) 20 ml/kg ver-
sus 30 ml/kg (strata a and b) in terms of the proportion of
children with fatal outcome 28 days after randomisation.
Primary outcome analysis will use time-to-event methods
(Kaplan-Meier, log-rank test, proportional hazards models)
to the timepoints specified for primary and secondary out-
comes, stratified by centre and anaemia severity at base-
line. Correction of anaemia will also be analysed using
time-to-event methods.
Pre-specified subgroup analyses will include each of
the other randomised allocations (ie exploration of inter-
actions in the factorial design), together with the other
randomisation stratification factor (centre) and the an-
aemia stratification factor (a versus b) for the transfusion
randomisation. We will also investigate a priori whether
there was any evidence for a different impact of the inter-
ventions according to the following categorical variables:
previous receipt of a transfusion (ever or at another health
centre in this illness); speed (rate) at which the transfusion
is administered; fever; malaria; microbiological evidence of
sepsis (blood culture or retrospective molecular diagno-
sis); HIV; known or previously undiagnosed sickle cell
disease.
For the cotrimoxazole prophylaxis and MVMM sup-
plementation randomisations the primary analysis will
be intention-to-treat based on all randomised partici-
pants, as above. However, secondary analyses will be re-
stricted to: (i) patients discharged alive, and (ii) patients
discharged alive in whom these interventions were nei-
ther mandated nor contraindicated (ie excluding HIV-
infected children and those with known GP6D deficiency
from the cotrimoxazole randomisation, and excluding
children admitted for severe acute malnutrition from the
supplementation randomisation).
Secondary outcome measures will be analysed using
time-to-event methods or normal linear regression for
continuous variables. The frequency of hospital re-
admissions and adverse events will be tabulated by body
systems and by randomised groups, and the number of
events experienced by each participant will be compared
across randomised groups using Fisher’s exact test.
For the within-trial cost-effectiveness analysis, the dif-
ferential cost of the treatment interventions will be re-
lated to their differential outcomes in terms of the
primary outcome. The relative cost-effectiveness of the
alternative forms of management will then be assessed
using standard decision rules and a full stochastic ana-
lysis will be undertaken. A cost-utility analysis will also
be conducted using a standard approach. The within-
trial analysis will be augmented by extrapolation beyond
the trial follow-up using decision-analytic modelling.
The aim of this analysis will be to predict the implica-
tions of any difference in clinical endpoints in the trial
for subsequent quality-adjusted survival duration and
long-term resource costs. This will inform the question
of whether any differences in drug costs between the
treatment groups are offset by reduction in other treat-
ment costs or health improvements in the long term.
Safety and ethical issues
Consent process for severe life-threatening anaemia
A number of children will present as emergencies where
delay in study enrolment, and thus treatment, through a
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consent procedure would be unacceptable. For the FEAST
trial we developed and received ethical approval to use a
two-stage consent process in this circumstance [39] and
subsequently evaluated the views and experiences of key
stakeholders (parents, nurses and clinicians) [40]. Verbal
assent will be sought from parents or guardians by the
admitting medical team, if it is considered that the full
consent process would significantly delay treatment allo-
cation, and consequently could be detrimental to the
child’s health. Full consent will be sought once the child’s
clinical condition has been stabilised. Caregivers will be
provided with a brief verbal description of the trial and
will be given the opportunity to ‘opt out’ of clinical re-
search. The clinician will later sign the verbal assent form,
which will be filed with the consent form. However, if a
child is enrolled on verbal assent by the guardian or
guardian and dies before informed consent is obtained,
the local and Imperial College Research Ethics Committee
have approved that informed consent will not be obtained
in these cases but that their data will be included in the
overall analysis.
Treatment strategies
Owing to high demand for blood for transfusion and
limited resources each day the clinical teams will check
with the transfusion services the quantities of blood
available for transfusion. Screening and enrolment will
not occur if there are no current supplies of blood and
when stocks are limited and screening and enrolment
will only be conducted for children without severe
complicated anaemia (eligible for R1a strategies) since
this group would ordinarily receive blood transfusion.
Children with uncomplicated anaemia (eligible for R1b
strategies) will only be enrolled on days where blood
transfusion supplies are judged to be adequate. The
numbers of patients enrolled each day will vary from site
to site and depend upon blood supplies and requirement
by non-study children.
Both MVMM and cotrimoxazole prophylaxis have been
widely used in children with minimal risk. Although sub-
stantial efforts have been made to ensure the safety of
blood, failure to correctly cross-match and/or infected
blood have the potential to cause harm. The trial will dir-
ectly evaluate whether these potential risks are out-
weighed by improved survival. TRACT teams are working
closely with the local blood transfusion services (BTS) to
ensure that recommended safety and quality control prac-
tices are being maintained.
A pilot study conducted in 2 sites in Uganda in 160
children fulfilling TRACT eligibility criteria evaluated
the safety of the higher volume of whole blood transfusion
proposed (30 ml/kg) compared to the standard volume
(20 ml/kg) – ClinicalTrials.Gov NCT01461590. The trial
study was able to demonstrate safety, and qualitative data
on feasibility and operational components of implementa-
tion of the study protocol, adherence to volumes of trans-
fusion and efficacy [41].
The trial will be recruiting patients with severe and
complicated anaemia with a high mortality. At the start
of the trial all sites will receive emergency care training,
including triage of those at highest risk. All patients will
be closely monitored so that clinical deteriorations can
be identified at the earliest opportunity and appropriate
therapy initiated. In general the trial sites in Africa have
considerable experience with this population and this
will serve to minimise the risks to the patients and the
trial. A detailed risk assessment will be conducted prior
to starting the trial.
The principles of the International Conference on
Harmonisation Good Clinical Practice (ICH GCP)
guidelines require that both investigators and sponsors
follow specific procedures when notifying and reporting
adverse events or reactions in clinical trials. Severe ad-
verse event management follows a dedicated SOP devel-
oped for the previous FEAST trial. Blood samples are
required from all study children. However, the volumes
of blood required would be minimised wherever possible
and be kept well within the maximum locally agreed
volumes.
Discussion
The operationalisation of a transfusion trial, investigat-
ing more liberal strategies in terms of which children
with SA would benefit from a transfusion and how much
to transfuse (in terms of volume), resulted in a number
of logistic, scientific and ethical challenges. Whilst the
demand for blood for transfusion is high in sub-Saharan
Africa, with children under 5 years and women of repro-
ductive age accounting for over 75 % of all transfusions,
stocks of blood for transfusion remain limited. Although
the data are very old and not comprehensive (from
2004) the WHO estimates that the minimum blood re-
quirement for countries in sub-Saharan Africa to be 10
to 20 units per 1000 population per year; yet on average
only 2.3 units of blood are donated per 1000 population
[42, 43]. This poses a major threat to the operational
feasibility of the trial reliant upon busy, over-burdened
blood transfusion services that face acute shortages of
blood when demand is high, especially during malaria
seasons [44]. Added to this were concerns raised about
the safety of using a larger volume of blood for transfu-
sion as proposed in the trial.
In our justification for the trial, we distilled these con-
cerns into three key elements. First, the safety aspects of
increased transfusion volume. We also considered that
this concern should extend to the number of repeat
transfusions received during admission, rather than the
just the volume of blood given per transfusion. Second,
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the potential that more liberal strategies may increase
demand for blood and divert scarce resources and fi-
nally, the difficulties in providing accurate volumes of
blood to ensure minimal wastage and reliable protocol
adherence. At the design phase of the trial we noted that
the published scientific literature on all these aspects
was sparse. With regards to repeat transfusions, a sub-
analysis of the FEAST trial recently published indicates
that of 1422 children transfused, 322 (23 %) received 2
or more transfusions, the proportion being greater (212/
612, 35 %) in those with hemoglobin < 4 g/dl at enrol-
ment [4]. Thus, multiple transfusions, occurring in
routine practice, not only incur additional resource util-
isation of both transfusion supplies and healthcare man-
power (across the whole chain of blood preparation,
transport, clinical management and monitoring of the
transfusion) but also expose children to the added risks
of infection, transfusion reaction and adverse events. In
addition, to test the safety of the higher volume pro-
posed for initial transfusion we conducted a pilot Phase
II trial (Tx30: ClinicalTrials.Gov: NCT01461590) [41].
The trial evaluated the safety and efficacy of a 30 ml/kg
whole blood versus 20 ml/kg (SOC) in 160 children
hospitalised with SA with respect to haematological re-
covery, adverse events and the need for additional trans-
fusion. We demonstrated a superior outcome in children
randomised to 30 ml/kg in terms of hemoglobin recov-
ery at 24 hours (the primary outcome) and through to
28 days (global p < 0.0001); averting the requirement for
repeat transfusion (5 % versus 15 %, p = 0.06) and with
no indication that the higher initial volume resulted in
an increase in adverse or fatal events compared to those
in the 20 ml/kg arm. The trial also demonstrated that
the use of digital scales to validate the accuracy of vol-
umes of blood supplied by transfusion service, simple
formulae and gauged blood burettes ensured reliable
protocol adherence and decreased wastage. The initial
volume actually infused followed randomisation strategy
(within 5 ml/kg) in 80 (98 %) patients in the 20 ml/kg
arm and 75 (96 %) in the 70 ml/kg arm [41]. We believe
these additional data provide reassuring support for
safety and feasibility of the TRACT trial.
To operationalise the trial on a day-to-day basis the
manual of operations stipulates that the clinical teams
must first check with the transfusion services that blood
is available and the adequacy of stocks of blood packs. If
there are no supplies then at these times no screening
and enrolment to the trial will occur. If, however, sup-
plies are at a critical level, children with severe and com-
plicated anaemia, eligible for R1a randomisation, should
be screened and enrolled since they would ordinarily re-
ceive a blood transfusion [3]. However, at times when
blood supplies are critically low then children with SA
(Hb < 6 g/dl) without complications (and thus eligible
for R1b randomisation) will not be enrolled to ensure
blood is not diverted for trial use.
One final issue pertinent to the transfusion strategies
is the potential for substantial variability of the haemato-
logical quality of the donor whole blood and red cell
concentrates. We anticipate that this would influence
haematological recovery and, therefore, have put in place
measures to quality control this aspect. For each pack of
blood transfused in the trial, prior to the blood being
run into the gauged transfusion burette, the nurse or
doctor will gently agitate the blood pack to ensure the
blood is thoroughly mixed and there is no settling of red
cells. Following this, the initial blood volume that will
run down the administration line from the gauged bur-
ette will have an aliquot run into a sterile apex tube
using an aseptic technique (to prevent contamination)
for Hb and haematocrit testing of the donor blood.
Trial status
Enrolment to the trial started September 2014 and is
currently ongoing. The 1000th patient was recruited on
7th June 2015.
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